"Flu remains a significant public health challenge, and mFLUSIVA provides an important new option for America's seniors. This approval also reflects the ongoing potential of our mRNA platform,” Moderna CEO Stéphane Bancel said.
The decision caps a seven-month review that included a rare refusal to consider the shot at all.
The U.S. Food and Drug Administration has approved Moderna's flu vaccine for people aged 50 and older, the company said on Wednesday, marking the first approval of a messenger RNA-based vaccine for seasonal flu.
mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved product Company expects supply to be available in select retailers in the coming weeks CAMBRIDGE, MA / ACCESS Newswire / August 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for u...
Moderna's vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.
Moderna on Tuesday said it has begun its first human trial of an experimental vaccine to protect against Bundibugyo ebolavirus, a strain of Ebola that has killed more than 1,650 people so far and currently has no approved vaccine.
Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines indicated Phase 1 trial is being conducted in Canada as part of our expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), building on Moderna's prior filovirus research CAMBRIDGE, MA / ACCESS Newswire / August 4, 2026 / Moderna, Inc. (NASDAQ:MRNA...
